Underdiagnosis of Tardive Dyskinesia: A Call for Better Recognition and Diagnosis
Tardive dyskinesia (TD) is a persistent movement disorder often associated with long-term antipsychotic use, yet it remains underreported and misdiagnosed in clinical practice.
Ultrasound in Tardive Dyskinesia: Enhancing Diagnosis and Treatment
Tardive dyskinesia (TD) can involve subtle or complex movements that are easily missed with visual inspection alone. In a recent study, three patients with orolingual and pharyngeal dyskinesias were assessed using point-of-care ultrasound, a tool that proved invaluable in diagnosing and managing their conditions.
Understanding Tardive Syndrome: A Spectrum of Symptoms
Tardive syndrome encompasses a range of persistent hyperkinetic, hypokinetic, and sensory phenomena resulting from chronic exposure to dopamine receptor blocking agents (DRBAs).
AIMS Training Boosts TD Screening and Outcomes in Outpatient Psychiatry
Despite the known risks, consistent screening for tardive dyskinesia (TD) in outpatient psychiatric settings remains limited, largely due to time constraints, underutilization of standardized tools like the Abnormal Involuntary Movement Scale (AIMS), and gaps in provider awareness and training.
Tardive Dyskinesia: 50 Years of Evolving Trends, Treatments, and Research
Despite the introduction of atypical antipsychotics, which carry a lower risk for parkinsonian symptoms, tardive dyskinesia (TD) has not been eradicated, as risk persists across all dopamine antagonists and partial agonists.
Tardive Dyskinesia: Challenges in Diagnosis, Management, and Treatment
Tardive dyskinesia (TD) is a complex iatrogenic movement disorder caused by prolonged dopamine receptor antagonism, often occurring in individuals on long-term antipsychotic medications.
Managing Tardive Dyskinesia: Early Detection and Effective Treatment Strategies
Tardive dyskinesia (TD) is an involuntary movement disorder caused by prolonged use of dopamine receptor-blocking agents, such as antipsychotic medications. While often irreversible, TD can severely impact a patient’s emotional, social, and professional life.
Exploring the Link Between Non-DRBD Medications and Tardive Dyskinesia
Tardive dyskinesia (TD) is most commonly linked to long-term use of dopamine receptor blocking drugs (DRBDs), such as antipsychotics. However, there has been some exploration of whether non-DRBD medications, like antidepressants, can also trigger similar movement disorders.
Managing Tardive Dyskinesia: Risk Factors, Early Detection, and Effective Treatments
Patients with conditions such as schizophrenia, bipolar disorder, and major depressive disorder are at high risk for developing tardive dyskinesia (TD). The risk is significantly higher in those treated with first-generation antipsychotics compared to second-generation antipsychotics (SGAs).
Advances in Tardive Dyskinesia Diagnosis and Treatment: Early Detection and VMAT2 Inhibitors
The clinical manifestations of tardive dyskinesia (TD) can be disruptive, with common symptoms including choreoathetotic and stereotypic movements, particularly in the mouth, jaw, tongue, and face.
